Tempus AI (TEMP) is set to report Q3 earnings, with analysts anticipating its first quarterly profit since going public. The precision medicine company's data business sustainability is under scrutiny, especially with its top five customers accounting for 59% of revenue and key contracts up for renewal .
Investors will be watching:
- Profitability: Expected EPS of $0.01, a significant turnaround from a $0.04 loss in Q2 .
- Data Revenue: Potential near-term risks as diagnostic peers enter data monetization and Tempus lacks exclusive EHR data rights .
- Pharma Partnerships: Expanded collaborations with Bristol Myers Squibb and Pathos AI could deliver up to $192.5M, bolstering data value .
Tempus AI faces profitability test as earnings loom Monday
INVESTING.COMNov 2, 9:52 AM UTC
0